Drug Trial Radar · NCT07664735
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Jun 2030
Study completion Sep 2030
Sponsor
- Lead sponsor
- Outpace Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.
Conditions
- Endometrial Cancer Recurrent
- Endometrial Cancer
- Advanced Endometrial Cancer
- Ovarian Cancer
- Ovarian Cancer Recurrent
- Platinum Resistant Ovarian Cancer
- Endometrial Cancers
Interventions
OPB-201Biological
A multi-transgene autologous TCR T cell therapy with optimized alpha and beta chains of a TCR specific for a peptide derived from PRAME and a designed protein which enhances TCR T cell potency.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths.Time frame: 2 years
- Incidence of dose-limiting-toxicities (DLTs)Time frame: 28 days
- To determine the maximum tolerated dose (MTD) of OPB-201 and/or recommended Phase 1b dose(s)Time frame: 2 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
UCSF - Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Emory - Winship Cancer Institute
Atlanta, Georgia · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.